Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
Rhea-AI Summary
Dianthus Therapeutics (Nasdaq: DNTH) has scheduled a conference call and webcast for September 8, 2025 at 8:00 a.m. EDT to discuss results from their Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG).
The clinical-stage biotechnology company, focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, will host the event with a Q&A session for registered participants. Investors can access the webcast through the company's website, with a replay available afterward.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, DNTH gained 20.00%, reflecting a significant positive market reaction. Argus tracked a peak move of +11.0% during that session. Argus tracked a trough of -52.4% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $142M to the company's valuation, bringing the market cap to $853M at that time. Trading volume was very high at 3.1x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT.
Investor Webcast & Conference Call Information
To access the live conference call by phone, please register here. Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.
A live webcast may be accessed through the Investors and Media section of the Company’s website, www.dianthustx.com. Following the call, a replay will be available at the same location.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
FAQ
When will Dianthus Therapeutics (DNTH) announce Phase 2 MaGic trial results for claseprubart?
How can investors access Dianthus Therapeutics' Phase 2 trial results conference call?
What is claseprubart (DNTH103) being developed for by Dianthus Therapeutics?
Will there be a replay available of Dianthus Therapeutics' Phase 2 trial results presentation?
